wayground logo

Free Printable Worksheets

NEW

Font size

S
M
L
XL
Worksheets

CLPT, M.Pharmacy, Pharmaceutics; Regulatory Affairs

Total questions: 30

Worksheet time: 30mins

Name
Class
Date
1.

CFR TITLE 21, CHAPTER 1, The 200 and 300 series are regulations pertaining to ...............

a)

Cosmetics

b)

Pharmaceuticals

c)

Food

d)

Medical devices

2.

CFR TITLE 21, CHAPTER I, The 600 series covers

a)

Cosmetics

b)

Drug products

c)

Biological products.

d)

Medical devices

3.

CFR TITLE 21, CHAPTER I, The 800 series are for ..........

a)

Medical devices

b)

Cosmetics

c)

Drug products

d)

Biological products

4.

Title 21 of the CFR is reserved for rules of the .........

a)

Food and Animal Drug Administration

b)

Drug and Cosmetics Administration

c)

Food and Cosmetics Administration

d)

Food and Drug Administration

5.

TYPES OF SOLID ORAL DOSAGE FORMS

a)

Tablets and capsules

b)

Powders

c)

Granules

d)

All

6.

FACTORS AFFECTING IN VITRO DRUG PRODUCT DISSOLUTION

a)

Solubility of the Drug Substance

b)

Polymorphism

c)

Salt Factor and “pH” of the Diffusion Layer

d)

Surface Area and Particle Size

e)

All

7.

The dissolution rate generally decreases as the stirring rate or dissolution speed is increased.

a)

True

b)

False

8.

The apparatus most commonly used for studying the dissolution of solid oral dosage forms. The basket at 100 rpm is commonly used for testing capsules and the paddle at 50 rpm for tablets.

a)

True

b)

False

9.

The USP Apparatus 1 is paddle and USP Apparatus 2 is basket

a)

True

b)

Flase

10.

For drugs that are weak acids, the dissolution rate increases with increasing pH, whereas, for weak bases, the dissolution rate decreases with increasing pH.

a)

True

b)

False

11.

APPLICATIONS OF IN VITRO DISSOLUTION

a)

Product Development

b)

Quality Assurance

c)

Product Stability

d)

Comparability Assessment

e)

Above all

12.

Abbreviated new drug application (ANDA) is submitted to the FDA’s ..........

a)

CBER

b)

CDER

c)

CHER

d)

None

13.

ANDA is termed “Abbreviated” because they generally need not include preclinical & clinical data to establish safety & effectiveness.

a)

True

b)

False

14.

For ANDA, the BIOEQUIVALENCE (BE) is established when the ratio of Test/Reference of the PK parameters for rate (Cmax) , AUC of log transformed data meet the 90 % confidence intervals of 80 -125 %.

a)

True

b)

False

15.

ANDA standard review time will likely be 10 months from submission and priority review would be eight months from submission.

a)

True

b)

Flase

16.

What is the standard review time for a New Drug Application NDA?

a)

5 months

b)

6 months

c)

10 months

d)

8 months

17.

How long does FDA, NDA priority review take?

a)

6 months

b)

10 months

c)

5 months

d)

8 months

18.

Generic drug products must be both pharmaceutically equivalent and bio-equivalent to be considered therapeutically equivalent and therefore approvable.

a)

True

b)

Flase

19.

The FDA recommends that in vivo bioequivalence studies be conducted in individuals that are representative of the general population, taking into account age, sex, and race factors.

a)

True

b)

False

20.

Postapproval changes could potentially affect the identity, strength, quality, purity, and potency of the finished product and therefore must be fully evaluated before implementation to determine any impact on the finished product, as it may relate to safety or effectiveness.

a)

True

b)

False

21.

The responsibility of an applicant does not end with approval of an NDA/ANDA the focus simply changes post-approval to ensuring approved drug products “remain” safe and effective and “accessible” to the public.

a)

True

b)

False

22.

ADE means

a)

Adverse drug effect

b)

Adverse drug reaction

c)

Adverse drug experience

d)

Adverse drug reason

23.

Types of ADE Reports:

a)

Serious and unexpected

b)

Serious and expected

c)

Nonserious and expected

d)

Nonserious and unexpected

e)

All above

24.

Post-marketing Surveillance means

a)

Phase 4

b)

Phase 3

c)

Phase 2

d)

Phase 1

25.

Postmarketing surveillance (PMS) is the practice of monitoring the safety of a pharmaceutical drug after it has been released on the market and is an important part of the science of pharmacovigilance

a)

True

b)

False

26.

Outsourcing is the business practice of hiring a party outside a company to perform services and create goods that traditionally were performed in-house by the company's own employees and staff.

a)

True

b)

False

27.

Bioavailability describes the concentration of drug in systemic blood in relation to the amount of drug given.

a)

True

b)

False

28.

Bioequivalence: It is a relative term which denotes that the drug substance in two or more identical dosage form, reaches the systemic circulation at the same relative rate and to the same relative extent i.e; their plasma concentration-time profiles will be identical without significant statistical differences

a)

True

b)

False

29.

Typical services outsourced for BA-BE studies:

a)

Bioanalytical studies

b)

Clinical Study Design

c)

Clinical Protocol Development

d)

Clinical Conduct

e)

All above

30.

CRO means

a)

Contract Research Outsourcing

b)

Contract Research Organ

c)

Contract Research Organization

d)

Contract Research Output